News
The CureNET Project hosts its first annual golf tournament
Brittany Holzhauer had her whole future planned. A self-professed “dreamer” with incredible determination, she started her career as pharmacist in 2018 and with her husband Luke, welcomed her first child, Lorelei, in June of 2019.
From Education to Experience: How one family’s NET experience led to better educational resources for NET patients and families.
“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.” Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here.
NETRF-funded Research Sets the Stage for Study Exploring Use of Terbium-161 in NETs
A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.
Study Focuses on Matching Patients with Rare Cancers and Cancer of Unknown Primary to Targeted Treatments
A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).
“It was my students’ idea…”
Warwick, NY middle school Ukulele club raises $6,000 for NETRF
A Champion for NETRF
“Anything that I have done, and any impact I have made in support of NETRF is because of the lessons he taught me.” Erica Roberts, NETRF Champion Society Member
“In my heart, I don’t ever want anyone to experience what we endured.”
After Leanne lost her husband of 31 years to pancreatic neuroendocrine cancer (pNETs), she sold his most beloved possession, a Bass boat, and donated half of the proceeds to NETRF. Leanne, her son Justin and their family and friends have raised more than $35,000 in Michael’s name for NETRF. She shares their story.
New Clinical Trial Testing Chemotherapy After Surgery in High-Risk pNETs
A new phase II clinical trial is exploring the effects of two approved chemotherapy drugs administered after surgery to treat adult patients who have high-risk, well-differentiated pancreatic neuroendocrine tumors (pNETS).
Faces of Philanthropy:
Joe Castrovinci
Joe Castrovinci has been living with NETs (and living well!) since his diagnosis in 2012. Read about his NET journey and why he and his husband have included NETRF in their estate planning.
Brandon’s Extraordinary Legacy
He was just FUN. Simply the nicest guy – always thinking of others. Perpetually positive – he only saw the glass as ‘half full.’ He